Home
 /
Papers
 /
Microbiology
 /
Immune receptor LILRB1 mediates cis-signalling which is targeted by RIFINs of the malaria parasite
Preprint
Open access
V1
Top 1% · Validated by QED

Immune receptor LILRB1 mediates cis-signalling which is targeted by RIFINs of the malaria parasite

Samuel G. Chamberlain, Marcus A. Widdess, Alexander M. Mørch +8 more
April 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.04.16.718981
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Microbiology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By revealing that LILRB1 signals in two distinct conformations—and that malaria RIFINs exploit both to disable NK cells—this work overturns the single-conformation receptor model and reframes how inhibitory immune signaling thresholds are set.

QED claims analysis

Summary

The malaria parasite Plasmodium falciparum has evolved two distinct clades of RIFIN proteins that suppress NK cell function by targeting different conformational states of the inhibitory immune receptor LILRB1: one clade binds elongated LILRB1 to trigger trans-signaling, while a second clade stabilizes a buckled LILRB1 conformation that enhances cis-signaling through MHC class I on the same cell surface, representing the first experimental demonstration of functional cis-signaling through an inhibitory immune receptor and revealing how pathogens exploit conformational dynamics to evade immune surveillance.

See full analysis
Main Claim 1 –

D3-RIF binding buckles LILRB1 into c-shaped conformation

Supporting evidence

  • D3-RIF stabilizes solution LILRB1 shift from extended to buckled
  • Different D3-RIFINs stabilize distinct buckled LILRB1 conformations
Main Claim 2 –

D3-binding RIFINs suppress NK function via LILRB1

Supporting evidence

  • Distinct RIFIN clade binds LILRB1 D3D4 domains
  • D3D4-binding RIFIN clade binds LILRB1 and induces buckling
  • D3D4-binding RIFINs occur across diverse Plasmodium falciparum strains
  • D3-binding RIFINs more potently suppress primary NK cells
Main Claim 3 –

Engineered disulfide bonds lock LILRB1 in buckled state

Supporting evidence

  • BUCLD locking accelerates D3-RIF binding by removing buckling step
Main Claim 4 –

Buckled LILRB1 forms cis complexes with MHC class I

Abstract

The malaria parasite, Plasmodium falciparum, replicates within human erythrocytes, where it is susceptible to clearance by immune cells. It uses erythrocyte surface proteins, the RIFINs, to signal through immune receptors and to suppress immune cell function. Previous studies identified two groups of RIFINs which bind different sites on inhibitory immune receptor LILRB1. While some RIFINs bind an elongated LILRB1 conformation, triggering inhibitory immune signalling in ‘trans’, we show that other RIFINs stabilise a c-shaped LILRB1 conformation. This buckled LILRB1 binds MHC class I found on the same immune cell, which triggers inhibitory ‘cis’ signalling. Therefore, LILRB1 exists in dynamic equilibrium, with an elongated conformation able to bind to ligands in ‘trans’ on a target cell, while a buckled conformation signals through MHC class I in ‘cis’, setting the signalling threshold. Different clades of RIFINs exist to mediate inhibitory signalling through each of these LILRB1 conformations to prevent parasite destruction.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?